logo
India's trade dilemma: Shield farmers, textiles or risk US cotton tariffs

India's trade dilemma: Shield farmers, textiles or risk US cotton tariffs

With two weeks to avoid US President Donald Trump's punitive 50 per cent tariffs, Prime Minister Narendra Modi has drawn a red line. India, he says, 'will never compromise on the interests of its farmers, livestock producers, and fisherfolk.'
That commitment is partly dictated by realpolitik. Nearly half of India's workforce relies on agriculture, a degree of dependence that has increased since the pandemic. It is very hard for a leader to make any concession that appears to let down the very people who have, starting in the 1960s, made the world's most-populous nation self-sufficient in food and dairy — in the face of tremendous constraints.
But paeans to the farmer do nothing to alter the harsh economic reality. Even if New Delhi says that a trade war with the US is the price it would pay for shielding growers from a deluge of American corn, soy, and cotton, it isn't clear that local farmers will be grateful for the protection. For the most vulnerable among them won't benefit from it.
Already, international apparel buyers are canceling or suspending orders, thanks to Trump's 50 per cent tariff threat. How would India deliver decent returns to farmers on their cotton crop if demand swoons in its biggest overseas market for shirts, trousers and T-shirts? Modi wants his fellow citizens to buy things made with the 'sweat of our people.' But with a belligerent Washington threatening to upend a vast swathe of local factory jobs, there will be less money at home to buy domestically produced goods. Tamil Nadu's garment-exports hub in southern India alone is responsible for 1.25 million paychecks.
Losing access to the US consumer may hurt India's farm economy more than slashing its 39 per cent average tariff on imported produce. In fact, Pakistan may have played Trump better. It has a significant cotton-growing population as well. But last year it became the world's largest buyer of US cotton, which it imports duty-free. It might take in more now to appease the White House.
India's textile industry, too, has asked the government to let go of the 11 per cent duty on short-staple fiber if it helps sell more of locally manufactured garments at Walmart and Target. After all, this tariff isn't really helping the farmer. Domestic cotton production is languishing at a 15-year low even though 44 per cent of the output hitting the market is being scooped up by a state agency at government-assured minimum prices.
The crop in neighboring Pakistan has fared even worse. But at least with a competitive 19 per cent tariff, the apparel industry there can hope to expand its market share in the US. Indian exporters, meanwhile, are staring at a much higher tax — after paying nearly 13 per cent more for the main raw material than the prevailing international price.
Cotton is just one example. Domestic prices of most agricultural produce are higher than internationally. While lavish farm subsidies in rich nations make their surpluses globally competitive, New Delhi's elaborate apparatus of state intervention largely channels the difference between local and international prices toward middlemen. Crop yields are abysmal, and climate change is making farm incomes increasingly erratic even behind high trade barriers. The poultry industry is struggling with feed costs, yet tariffs of 45 per cent-56.5 per cent make US soy meal too expensive. If India allows its farmers to grow genetically modified food, they may be able to hold their own against American corn and soybean.
At $32 billion, agricultural imports are low for a country of 1.4 billion people; and even this figure is padded by palm oil brought in from Indonesia and Malaysia. The US accounts for less than $2 billion of the total. Why not switch sourcing to US soybean oil and make it duty-free to give Trump a win?
More broadly, why not exploit Trump's tariff shock to rewire unproductive agriculture and lift stagnant manufacturing? India has 126 million people answering to the description of farmers even though their landholding is less than five acres. As a 2023 survey of marginal producers showed, their 60,000 rupees ($700) average annual income from selling crops is often less than what they earn from a second occupation as daily-wage labor. They're stuck on the land because of food security — and because the urban economy has nothing for them.
Just about one in 10 families has someone in a salaried job, and only a third of these farmers take advantage of state procurement at pre-announced prices. Others sell to private traders. The most popular government support program for this group is straight-up cash in bank accounts; it would stop if they were no longer holding on to the land.
Yet the taxpayer is picking up the bills for keeping the land cultivated when imports would be cheaper; and for shielding urban workers from the high costs of locally grown produce. Lest expensive food crush the country's dream of industrialization, the government gives free rice and wheat to 800 million people so that their employers don't have to pay them high wages. Throw everything into the mix, and the annual cost was in excess of $100 billion during the pandemic. If the tariff-related disruption turns out to be worse than Covid-19, as some exporters fear, then the fiscal drag might only become heavier.
Four years ago, Modi was forced to withdraw legislation whose basic premise was to give farmers more freedom to discover free-market prices. If that was a poorly designed makeover, striking a defiant note against a mercurial US president in the name of agricultural interests is also ill-conceived. But with the prime minister's political opponents stepping up their campaign against his 11-year-old rule, it's irrational to expect meaningful reforms. Politics will triumph over economics.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

'India's freedom of speech regulated by Israel?': Congress questions after envoy Reuven Azar ‘targets' Priyanka Gandhi
'India's freedom of speech regulated by Israel?': Congress questions after envoy Reuven Azar ‘targets' Priyanka Gandhi

Mint

time14 minutes ago

  • Mint

'India's freedom of speech regulated by Israel?': Congress questions after envoy Reuven Azar ‘targets' Priyanka Gandhi

Congress leader Pawan Khera on Wednesday, launched a scathing attack on Israel Ambassador Reuven Azar after his criticism of Priyanka Gandhi Vadra, who had accused Tel Aviv of 'genocide' and criticising the Indian government for its 'silence' on the matter. In a strongly worded post on social media platform X, Khera slammed Reuven Azar, stating that him 'targeting' a sitting Member of the Indian Parliament is 'both unprecedented and intolerable.' The Congress leader further tagged S Jaishankar, questioning if 'freedom of speech in India' had now 'begun to be regulated from Israel." Following Priyanka Gandhi's post on X, Israeli Ambassador to India Reuven Azar accused the Congress leader of spreading 'deceit' and presented Israel's version of the conflict's toll. 'What is shameful is your deceit. Israel killed 25,000 Hamas terrorists. The terrible cost in human lives derives from Hamas's heinous tactics of hiding behind civilians, their shooting of people trying to evacuate or receive assistance and their rocket fire,' Azar said in his post. The Israeli diplomat's post comes after Priyanka Gandhi alleged that Israel 'murdered over 60,000 people, 18,430 of whom were children', starved hundreds to death, and was threatening to starve millions more. 'Enabling these crimes by silence and inaction is a crime in itself. It is shameful that the Indian Government stands silent as Israel unleashes this devastation on the people of Palestine,' she wroteon X, on Tuesday. Apart from Pawan Khera, Congress's Gaurav Gogoi also hit out at the Israeli ambassador, stating that the 'Parliament cannot remain a passive spectator.' "The disparaging comments made by a foreign Ambassador against a Member of Parliament of India is a serious breach of privilege. Even if the Union Government is silent, the Parliament cannot remain a passive spectator..." he said on X. Veteran Congress leader and former Union Minister Anand Sharma also strongly condemned the remarks of the Israeli Ambassador to India, "denying" the humanitarian crisis of Gaza, saying that the language used by the Israeli representative and "undiplomatic, distasteful and unacceptable," while the brutality, destruction of schools, hospitals and mass starvation is taking place. As Israel continues its bombardment, the IDF said it has approved the "framework" for a new offensive in the Gaza Strip, days after the security cabinet called for the seizure of Gaza City, reported AFP. On Tuesday, Gaza's Health Ministry reported that five more Palestinians have died from hunger, bringing the total number of starvation-related deaths to 227, including 103 children.

Nifty Pharma index rises 1.9%:  Alkem, Zydus among key gainers: Should you buy or sell pharma stocks?
Nifty Pharma index rises 1.9%:  Alkem, Zydus among key gainers: Should you buy or sell pharma stocks?

Mint

time14 minutes ago

  • Mint

Nifty Pharma index rises 1.9%: Alkem, Zydus among key gainers: Should you buy or sell pharma stocks?

Stock Market Today: The Nifty Pharma index gained 1.9% during the intraday trades on Wednesday. Alkem and Zydus stood among key gainers that led the rally The Nifty Pharma Index gained almost 2% during the intraday trade on Wednesday amid a relief rally in the Indian stock market. The Nifty Pharma Index opened at 21,803.45 levels, higher than the previous day's closing price of 21,753.50. It continued to gain further to an intraday high of 22,171.05, which meant gains of almost 2% over the previous day's close. Alkem Laboratories, Zydus Lifesciences, Laurus Labs, and Abbott India were among the key gainers that led to the rise in the Nifty Pharma pack. The US market remains critical for many Indian pharma companies. Sun Pharmaceuticals, Lupin , Dr. Reddy's, Aurobindo, Cipla, and many more derive a significant part of revenues from the US markets. Thus the danger of a 50% tax on pharmaceuticals looms, and this clearly poses a risk to the profitability of Indian pharmaceutical businesses, which rely on the US market for 30-50% of their sales. Most of these US revenues, however, come from the generic drug segment. Silver lining The silver lining remains as India remains cost-competitive compared to both the US and global peers, which should help mitigate some risks, said Ajit Banerjee, president and chief investment officer at Shriram Life Insurance. The domestic Indian pharma market (50% of the Indian pharmaceutical market) will remain unaffected by tariffs. Within the US, the impact on the generic formulations market is still uncertain, though Indian players already operate on thin margins. Tariffs could increase the drug shortages by eliminating competition in a market where pricing pressures are already intense, which could be a positive for Indian companies over the mid- to long-term, highlighted Banerjee While the recent executive order by the US Administration excludes the pharmaceutical sector from immediate tariff imposition. Any tariff action will depend on the outcome of the ongoing investigation under Section 232 of the Trade Expansion Act of 1962. Even if the India pharma tariff question is answered, Kotak Institutional expect the uncertainty to persist around whether the anticipated pharma tariffs (post the Section 232 investigation) would add to the country-specific one, definition of pharma/pharma products and then eventually how much of the tariffs are passed on and rolled back Bannerjee believes the US can either bring manufacturing back home or reduce drug prices, but not both simultaneously. Even before tariffs are finalized, the uncertainty can lead to delays in order commitments and impact sector sentiment and stock price thereby. The sector currently trades at a 1Y forward P/E of 29.7 times, above its 10-year average of 26.7x. We see tariff-induced volatility as a chance for investors to accumulate quality pharma stocks on dips, said Banerjee. Nifty Pharma has witnessed two weeks of selling pressure, especially after the recent U.S. tariff developments, as per analysts. The Pharma Index was trading near a support level on the daily time frame, where a pause in the decline was expected in the coming days, potentially leading the index towards 21,998. The outlook remains negative as long as the index fails to sustain above 22,380. On the downside, a break below 21,240 could push the index further towards the 20,380–20,140 zone, as per Kunal Kamble, Sr. Technical Research Analyst at Bonanza * Disclaimer: The views and recommendations above are those of individual analysts or brokerage companies, not Mint. We advise investors to check with certified experts before making any investment decisions.

Bulls ride high on India stocks, expecting success of US-Russia talks on Ukraine
Bulls ride high on India stocks, expecting success of US-Russia talks on Ukraine

Mint

time14 minutes ago

  • Mint

Bulls ride high on India stocks, expecting success of US-Russia talks on Ukraine

Bulls appeared to be taking charge of the stock markets on Wednesday, ahead of the Trump-Putin talks, where a breakthrough or an impasse could significantly impact Indian equities. The two leaders are slated to meet in Alaska on Friday in a bid to end the over-three year Ukraine war. A day after foreign portfolio investors trimmed their index future longs to 7.95%, only 20 basis points shy of the record low of 7.75% on 22 March 2023, in light of the US Fed rate tightening cycle, bulls sold huge quantities of put options between the 24,500 and 24,600 levels, expecting a rally in the markets ahead of the talks. The contracts expire tomorrow. The Nifty 50 traded 0.6% higher at 24,634 at 1 pm. Amid likely domestic institutional investor buying in the cash market, bulls sold a massive number of puts at 24,600 – the open position at this strike rose by a whopping 227,758 contracts to a total 284,785 contracts. At 24,550, the open or outstanding positions jumped 148,077 contracts to 193,635 contracts and at 24,500 by 152,528 contracts to 260,034 contracts. The jump in open positions at these levels indicates that bulls expect the markets to close at or above 24,600, which will enable them to pocket the premium paid by the put buyers, who expect the markets to correct. "The correction premise (of put buyers) is based on the talks stalling and a continuation of the war, which could impact countries like India that buy Russian oil and have been slapped with a proposed punitive tariff of 25% from 27 August," explained SK Joshi, a consultant with Khambatta Securities. Other analysts cautioned that it was too early to take such calls because the Indian markets would react to the outcome of the talks only on Monday, with Friday a holiday for Independence Day. "The market is likely to consolidate in a 24,400-24,700 range ahead of the Russia-US talks in Alaska," said Sahaj Agrawal, head of derivatives research at Kotak Securities. "The reaction to the outcome will be on Monday." Options data and sentiment for now also suggest a sideways movement, with no major horizon shift on the cards, he added. The put-call ratio of the weekly options expiring on Thursday stood at 0.99 intraday, which means that for every 100 calls sold, traders had sold 99 puts. On Tuesday, the ratio stood at 0.65, or only 65 puts sold for 100 calls sold. Time correction The benchmark Nifty 50 has been in a time correction for 11 months now, which is longer than the nine-month time correction that followed the outbreak of the covid pandemic in 2020. Time correction implies an extended period of stagnant to marginally lower price movement. The Nifty has fallen 6.25% from a record high of 26,277.35 on 27 September last year to Wednesday's intraday level of 24,634. While the Nasdaq, the UK's FTSE and Japan's Nikkei trade at record highs, Indian stock indices haven't been able to reclaim their previous high even 11 months later. In the last major down-cycle, the Nifty fell 40% from a high of 12,430 on 20 January 2020 to 7,511.10 on 24 March that year when the pandemic surfaced. However, it reclaimed the high in nine months, closing at 12,632 by 9 November. The current time correction is due to tepid earnings growth and more lately because of Trump's crushing tariffs on India, which Moody's expects could trim its current fiscal growth estimate by 30 bps to 6%. "We have been in a time correction for nearly 11 months now and will have to see how the geopolitical events play out to reckon whether we will break through the 26,277.35 record high of last September or test the multi-month low of 21,743.65 of this April," Kotak Securities' Agrawal added.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store